Relypsa, Inc. was a big mover last session, as its shares rose almost 9% on the day. The stock shot up following the FDA rejection of the potassium-lowering drug ZS-9 of AstraZeneca PLZ (AZN - Free Report) . This bodes well for Relypsa as its potassium-lowering drug, Veltassa, has been approved in Oct 2015. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the trend for the company since May 2, as the stock is now trading above the volatile price range of $13.51 to $17.82.
Over the last 30 days, the company witnessed four positive and six negative estimate revisions. Meanwhile, the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s move higher lasts.
Relypsa currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is RLYP going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Relypsa, Inc. was a big mover last session, as its shares rose almost 9% on the day. The stock shot up following the FDA rejection of the potassium-lowering drug ZS-9 of AstraZeneca PLZ (AZN - Free Report) . This bodes well for Relypsa as its potassium-lowering drug, Veltassa, has been approved in Oct 2015. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the trend for the company since May 2, as the stock is now trading above the volatile price range of $13.51 to $17.82.
Over the last 30 days, the company witnessed four positive and six negative estimate revisions. Meanwhile, the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s move higher lasts.
Relypsa currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is RLYP going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AZN - FREE